It was a delight to catch up with Dr. Bruce Prenner (Allergy Associates Medical Group Inc., San Diego, CA, USA) to discuss the findings from a survey investigating referral sources, etiology, prevalence, symptoms and treatments in chronic cough patients.
The abstract ‘Chronic Cough: Referral Sources, Etiology, Prevalence, Symptoms and Treatments In Adults A Survey of Allergy Specialists‘ was presented at AAAAI 2022, 25-28 February.
- What was the rationale for and design of your survey? (0:33)
- What were the most common symptoms and complaints of people living with chronic cough? (2:24)
- What were the most common treatments, and how effective were they? (4:35)
- On the basis of these findings, what unmet needs have been identified and what future actions should be taken? (7:03)
Disclosures: Bruce Prenner is a consultant for ALK, Merck; has received grant/ research support from Merck, Bellus, Shionogi, Teva, Aldeyra Therapeutics; has served on advisory boards for Merck; and has participated in speaker’s bureaus for Optinose, ALK, Merck.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the AAAAI annual meeting 2022.
Share this Video
Related Videos In Chronic Cough
Gefapixant for the treatment of chronic cough – a dose-response analysis: Elena Kum, ERS 2023
Gefapixant is a P2X3 antagonist that was recently studied in two phase 3 randomized controlled trials, COUGH-1 and COUGH-2, and is currently under regulatory review in Europe. In this interview, we were delighted to speak with Elena Kum (McMaster University, Hamilton, ON, Canada) around the aims, methodology and findings from her dose-response meta-analysis of gefapixant. […]
Alan Kaplan: The IPCRG Sentinel Network and Respiratory Q&A
We were delighted to meet with Prof. Alan Kaplan (University of Toronto, Toronto, ON, Canada) to discuss the international IPCRG Sentinel Network which represents each continent and includes over 100 primary care clinicians. The IPCRG is providing answers based on published peer reviewed evidence to COVID and respiratory questions from the Sentinel Network. Questions Could […]
James Wingfield Digby, ERS 2022: Hypotonic Saline in the Diagnosis of Refractory/Unexplained Chronic Cough
Chronic cough is a persistent cough lasting ≥8 weeks and is estimated to affect between 2-18% of the global population; however chronic cough is often unrecognized, underdiagnosed and there remain many unmet needs in its treatment. It was a pleasure to speak with Dr. James Wingfield Digby (University of Manchester, Manchester, UK) around his study […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!